Real-World check: does new psoriasis pill deliver?
NCT ID NCT06512337
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well the drug deucravacitinib works for adults with moderate plaque psoriasis in real-life clinics across China. Researchers will track skin clearance and symptom improvement in 153 people who are just starting the medication. The goal is to see if results from controlled trials hold up in everyday practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Guangzhou, Guangdong, 510091, China
-
Local Institution - 0002
Handan, Hebei, 056029, China
-
Local Institution - 0003
Beijing, 102218, China
-
Local Institution - 0004
Shanghai, Shanghai Municipality, 200080, China
-
Local Institution - 0005
Dalian, Liaoning, 116021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New oral pill TLL018 aims to clear psoriasis plaques in phase 2 trial
- Psoriasis drug may be safe for patients with fatty liver
- New cream shows promise for clearing psoriasis in chinese patients
- Could a simple skincare routine soothe psoriasis Flare-Ups?
- New psoriasis cream shows early promise in small trial
- New biologic drug netakimab tested in kids with psoriasis